TYRO3 and neoplasm: Tyro3 was reported to contribute significantly to tumor growth, aggressiveness and liver dysfunction in HCC (Duan et al., 2016) and was also considered a marker and therapeutic target for HCC with a higher hepatitis activity (Tsai et al., 2020).